Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Route 92 Medical announces first commercial cases in Canada following Health Canada Medical Device license for advanced neurovascular portfolio.
-
Raj Denhoy joined Route 92 Medical as Chief Financial Officer.
-
Route 92 Medical's $50 million growth financing will support acceleration of commercial growth. New investor Sectoral Asset Management joins round.
-
Route 92 Medical enrolls first patient in 500-patient, 50-center, SUMMIT RISE study evaluating the real-world performance of the company's devices.
-
Route 92 Medical Appoints Medtech Industry Leader Pat Mackin to its Board of Directors
-
Route 92 Medical filed a patent infringement suit against Balt alleging infringement of five U.S. patents protecting its Tenzing delivery technology.
-
Route 92 Medical announced results from an independent real-world study of its HiPoint Reperfusion System and plans for a 500-patient SUMMIT RISE study.
-
Route 92 Medical names med tech industry veterans Mitch Hill and Lucas Buchanan to its board of directors.
-
Route 92 Medical announces results of the SUMMIT MAX randomized clinical trial and receipt of a 510(k) clearance for the HiPoint 88 Reperfusion System.
-
Route 92 Medical and Q'Apel Medical have settled their patent litigation.